Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 8, 2007, Pages 925-931

  Kuruvilla, John ^a   Shepherd, John D ^a   Sutherland, Heather J ^a   Nevill, Thomas J ^a   Nitta, Janet ^a   Le, Aulan ^a   Forrest, Donna L ^a   Hogge, Donna E ^a   Lavoie, Julye C ^a   Nantel, Stephen H ^a   Toze, Cynthia L ^a   Smith, Clayton A ^a   Barnett, Micheal J ^a   Song, Kevín W ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Allogeneic stem cell transplantation; Graft versus myeloma; Multiple myeloma

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MAFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER STAGING; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34447530730     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.04.006     Document Type: Article

References (29)

1. Attal M., Harousseau J.L., Stoppa A.M., et al., Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
2. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
3. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
4. Blade J., Rosinol L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
5. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
6. Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., and Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 87 (1996) 1196-1198
7. Lokhorst H.M., Schattenberg A., Cornelissen J.J., Thomas L.L., and Verdonck L.F. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 90 (1997) 4206-4211
8. Bensinger W.I., Buckner C.D., Anasetti C., et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 88 (1996) 2787-2793
9. Couban S., Stewart A.K., Loach D., Panzarella T., and Meharchand J. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant 19 (1997) 783-789
10. Le Blanc R., Montminy-Metivier S., Belanger R., et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 28 (2001) 841-848
11. Alyea E., Weller E., Schlossman R., et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 32 (2003) 1145-1151
12. Byrne J.L., Fairbairn J., Davy B., Carter I.G., Bessell E.M., and Russell N.H. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission. Bone Marrow Transplant 31 (2003) 157-161
13. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88 (1996) 4711-4718
14. Reece D.E., Shepherd J.D., Klingemann H.G., et al. Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation. Bone Marrow Transplant 15 (1995) 117-123
15. Samson D., Gaminara E., Newland A., et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2 (1989) 882-885
16. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
17. Atkinson K., Horowitz M.M., Gale R.P., Lee M.B., Rimm A.A., Bortin M.M., and Committee of the International Bone Marrow Transplant Registry. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 4 (1989) 247-254
18. Blade J., Samson D., Reece D., et al., European Group for Blood and Marrow Transplant, Myeloma Subcommittee of the EBMT. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102 (1998) 1115-1123
19. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
20. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105 (2005) 4532-4539
21. Gahrton G., Svensson H., Cavo M., et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113 (2001) 209-216
22. Badros A., Barlogie B., Morris C., et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 97 (2001) 2574-2579
23. Kroger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
24. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
25. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
26. Bensinger W.I. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 20 (2006) 1683-1689
27. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97 (2001) 1566-1571
28. Jaksic W., Trudel S., Chang H., et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 23 (2005) 7069-7073
29. Kroger N., Schilling G., Einsele H., et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 103 (2004) 4056-4061